Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adams Looks To Mucinex Extensions; “Mr. Mucus” Marries

This article was originally published in The Tan Sheet

Executive Summary

Adams Respiratory Therapeutics sees additions to its Mucinex extended-release guaifenesin line as "key" to the firm's long-term growth strategy

You may also be interested in...



Adams Brings Mucinex To Pediatric Market; Humibid Launch Slated For March

Adams Respiratory Therapeutics will launch a line of cough/cold products for children under the Mucinex brand name by the end of 2006

Adams Brings Mucinex To Pediatric Market; Humibid Launch Slated For March

Adams Respiratory Therapeutics will launch a line of cough/cold products for children under the Mucinex brand name by the end of 2006

Adams Brings Mucinex To Pediatric Market; Humibid Launch Slated For March

Adams Respiratory Therapeutics will launch a line of cough/cold products for children under the Mucinex brand name by the end of 2006

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel